AR076170A1 - Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. - Google Patents

Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.

Info

Publication number
AR076170A1
AR076170A1 ARP100101039A ARP100101039A AR076170A1 AR 076170 A1 AR076170 A1 AR 076170A1 AR P100101039 A ARP100101039 A AR P100101039A AR P100101039 A ARP100101039 A AR P100101039A AR 076170 A1 AR076170 A1 AR 076170A1
Authority
AR
Argentina
Prior art keywords
alkyl
independently selected
arylalkyl
hydrogen
cycloalkyl
Prior art date
Application number
ARP100101039A
Other languages
English (en)
Inventor
Omar D Lopez
Lawrence G Hamann
Makonen Belema
Qi Chen
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42313493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR076170(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR076170A1 publication Critical patent/AR076170A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado por que tiene la Formula (1): o una de sus sales farmacéuticamente aceptables, en la que: s es 0 o 1; L es -L1-L2-, en los que L1 y L2 se seleccionan independientemente del grupo de formulas 2 con la condicion de que al menos uno de L1 y L2 sea distinto de la formula 3; Y e Y' son independientemente oxígeno (O) o NH; R1 es hidrogeno o -C(O)Rx; R2 es hidrogeno o -C(O)Ry; Rx y Ry se seleccionan independientemente de cicloalquilo, heteroarilo, heterociclilo, alcoxi y alquilo sustituido con uno o más sustituyentes seleccionados independientemente de arilo, alquenilo, cicloalquilo, heterociclilo, heteroarilo, -OR3, -C(O)OR4, -NRaRb y -C(O)NRcRd, en los que arilo y heteroarilo pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados independientemente de alquilo, haloalquilo, arilalquilo, heterociclilo, heterociclilalquilo, halogeno, ciano, nitro, -C(O)OR4, OR5, -NRaRb, (NRaRb)alquilo y (MeO)(HO)P(O)O-, y en los que cicloalquilo y heterociclilo pueden estar opcionalmente condensados con un anillo aromático y pueden estar opcionalmente sustituidos con uno o más sustituyentes seleccionados independientemente de alquilo, hidroxilo, halogeno, arilo, NRaRb, oxo, y -C(O)OR4; R3 es hidrogeno, alquilo o arilalquilo; R4 es alquilo o arilalquilo; R5 es hidrogeno, alquilo o arilalquilo; Ra y Rb se seleccionan independientemente de hidrogeno, alquilo, cicloalquilo, arilalquilo, heteroarilo, -C(O)R6, -C(O)OR7, -C(O)NRcRd, y (NRcRd)alquilo, o como alternativa, Ra y Rb, junto con el átomo de nitrogeno al que están unidos, forman un anillo de cinco o seis miembros o una estructura de anillo bicíclica con puente, pudiendo contener dicho anillo de cinco o seis miembros o dicha estructura de anillo bicíclica con puente opcionalmente uno o dos heteroátomos adicionales seleccionados independientemente de nitrogeno, oxígeno y azufre y pudiendo contener uno, dos o tres sustituyentes seleccionados independientemente de alquilo C1 a C6, haloalquilo C1 a C4, arilo, hidroxilo, alcoxi C1 a C6, haloalcoxi C1 a C4 y halogeno; R6 es alquilo; R7 es alquilo, arilalquilo, cicloalquilo o haloalquilo; R100 y R110 se seleccionan independientemente de hidrogeno, alquilo, cianoalquilo y halo; Rc y Rd se seleccionan independientemente de hidrogeno, alquilo, arilalquilo cicloalquilo.
ARP100101039A 2009-03-30 2010-03-30 Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden. AR076170A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16457909P 2009-03-30 2009-03-30

Publications (1)

Publication Number Publication Date
AR076170A1 true AR076170A1 (es) 2011-05-26

Family

ID=42313493

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101039A AR076170A1 (es) 2009-03-30 2010-03-30 Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.

Country Status (20)

Country Link
US (2) US20100249190A1 (es)
EP (1) EP2414352B1 (es)
JP (1) JP5612661B2 (es)
KR (1) KR20110134497A (es)
CN (1) CN102378762B (es)
AR (1) AR076170A1 (es)
AU (1) AU2010234861A1 (es)
BR (1) BRPI1014084A2 (es)
CA (1) CA2758047C (es)
CL (1) CL2011002453A1 (es)
CO (1) CO6361922A2 (es)
EA (1) EA021260B1 (es)
ES (1) ES2524542T3 (es)
IL (1) IL214939A0 (es)
MX (1) MX2011009644A (es)
NZ (1) NZ594981A (es)
PE (1) PE20120517A1 (es)
TW (1) TWI476190B (es)
WO (1) WO2010117704A1 (es)
ZA (1) ZA201106669B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG172352A1 (en) 2008-12-23 2011-07-28 Abbott Lab Anti-viral compounds
WO2010075380A1 (en) 2008-12-23 2010-07-01 Abbott Laboratories Anti-viral compounds
US8314135B2 (en) 2009-02-09 2012-11-20 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole antivirals
US8394968B2 (en) 2009-02-17 2013-03-12 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8242156B2 (en) 2009-02-17 2012-08-14 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
US8188132B2 (en) 2009-02-17 2012-05-29 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
TWI438200B (zh) * 2009-02-17 2014-05-21 必治妥美雅史谷比公司 Ｃ型肝炎病毒抑制劑
US8101643B2 (en) 2009-02-27 2012-01-24 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8673954B2 (en) 2009-02-27 2014-03-18 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US9765087B2 (en) 2009-02-27 2017-09-19 Enanta Pharmaceuticals, Inc. Benzimidazole derivatives
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201038559A (en) 2009-04-09 2010-11-01 Bristol Myers Squibb Co Hepatitis C virus inhibitors
US8143414B2 (en) 2009-04-13 2012-03-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102459165B (zh) * 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
KR20170041924A (ko) 2009-05-13 2017-04-17 길리애드 파마셋 엘엘씨 항바이러스 화합물
US8138215B2 (en) 2009-05-29 2012-03-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8211928B2 (en) 2009-05-29 2012-07-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
US9394279B2 (en) 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
CN103819537A (zh) * 2009-06-11 2014-05-28 艾伯维巴哈马有限公司 抗病毒化合物
US8221737B2 (en) 2009-06-16 2012-07-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8609648B2 (en) 2009-07-02 2013-12-17 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
JP2012533569A (ja) 2009-07-16 2012-12-27 ヴァーテックス ファーマシューティカルズ、 インコーポレイテッド フラビウイルス感染症を治療又は予防するためのベンゾイミダゾール類似体
MX2012002759A (es) 2009-09-04 2012-04-30 Glaxosmithkline Llc Compuestos quimicos.
US8759332B2 (en) 2009-09-11 2014-06-24 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
US8815928B2 (en) 2009-09-11 2014-08-26 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8703938B2 (en) 2009-09-11 2014-04-22 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8927709B2 (en) 2009-09-11 2015-01-06 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110269956A1 (en) 2009-11-11 2011-11-03 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110281910A1 (en) 2009-11-12 2011-11-17 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20110137633A1 (en) * 2009-12-03 2011-06-09 Abbott Laboratories Anti-viral compounds and methods of identifying the same
EP2512480A4 (en) 2009-12-14 2013-05-15 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011075607A1 (en) * 2009-12-18 2011-06-23 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8933110B2 (en) 2010-01-25 2015-01-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
MX2012008658A (es) 2010-01-25 2012-12-05 Enanta Pharm Inc Inhibidores del virus de la hepatitis c.
US8178531B2 (en) 2010-02-23 2012-05-15 Enanta Pharmaceuticals, Inc. Antiviral agents
US8623814B2 (en) 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
EA201201235A1 (ru) 2010-03-04 2013-04-30 Энанта Фармасьютиклз, Инк. Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv
EP2550267A1 (en) 2010-03-24 2013-01-30 Vertex Pharmaceuticals Incorporated Analogues for the treatment or prevention of flavivirus infections
WO2011127350A1 (en) 2010-04-09 2011-10-13 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
WO2011153396A1 (en) 2010-06-04 2011-12-08 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
JP2013531011A (ja) 2010-06-28 2013-08-01 バーテックス ファーマシューティカルズ インコーポレイテッド フラビウイルス感染の処置または予防のための化合物および方法
WO2012006055A2 (en) 2010-06-28 2012-01-12 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of flavivirus infections
WO2012021704A1 (en) 2010-08-12 2012-02-16 Enanta Pharmaceuticals, Inc. Hepatitis c virus inhibitors
AU2011292040A1 (en) 2010-08-17 2013-03-07 Vertex Pharmaceuticals Incorporated Compounds and methods for the treatment or prevention of Flaviviridae viral infections
RU2452735C1 (ru) * 2010-11-30 2012-06-10 Александр Васильевич Иващенко Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения
US20150031884A1 (en) * 2010-12-15 2015-01-29 Abbvie Inc. Anti-viral compounds
WO2012083170A1 (en) * 2010-12-16 2012-06-21 Abbott Laboratories Anti-viral compounds
CN106986862A (zh) 2010-12-22 2017-07-28 Abbvie 公司 丙型肝炎抑制剂及其用途
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9546160B2 (en) * 2011-05-12 2017-01-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
WO2012158861A2 (en) 2011-05-18 2012-11-22 Enanta Pharmaceuticals, Inc. Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
SG194681A1 (en) 2011-05-27 2013-12-30 Achillion Pharmaceuticals Inc Subsituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes useful for treating hcv infections
WO2013016499A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Methods for preparation of thiophene compounds
WO2013016501A1 (en) 2011-07-26 2013-01-31 Vertex Pharmaceuticals Incorporated Formulations of thiophene compounds
CN106166160A (zh) 2011-09-16 2016-11-30 吉利德制药有限责任公司 用于治疗hcv的组合物
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US9326973B2 (en) 2012-01-13 2016-05-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9012427B2 (en) 2012-03-22 2015-04-21 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
MD596Z (ro) * 2012-10-09 2013-09-30 Национальный Центр Общественного Здоровья Министерства Здравоохранения Республики Молдова Metodă de tratament al hepatitei virale cronice C la copii
KR20140119012A (ko) 2013-01-31 2014-10-08 길리어드 파마셋 엘엘씨 두 항바이러스 화합물의 병용 제형물
TW201526899A (zh) 2013-02-28 2015-07-16 Alios Biopharma Inc 醫藥組成物
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US9717712B2 (en) 2013-07-02 2017-08-01 Bristol-Myers Squibb Company Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus
US20150023913A1 (en) 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
EP3021845A1 (en) 2013-07-17 2016-05-25 Bristol-Myers Squibb Company Combinations comprising biphenyl derivatives for use in the treatment of hcv
SI3038601T1 (sl) 2013-08-27 2020-07-31 Gilead Pharmasset Llc Formulacija kombinacije dveh protivirusnih spojin
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
US10617675B2 (en) 2015-08-06 2020-04-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TWI732826B (zh) 2016-02-26 2021-07-11 大陸商江蘇恆瑞醫藥股份有限公司 一種新毒素及其中間體的製備方法
CN107987083A (zh) * 2017-11-24 2018-05-04 江苏亚盛医药开发有限公司 用于治疗和/或预防与肝炎病毒相关的疾病或病症的双二氮杂双环化合物
KR20240012476A (ko) 2021-05-21 2024-01-29 길리애드 사이언시즈, 인코포레이티드 지카 바이러스 저해제로서의 펜타사이클릭 유도체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5654451B1 (en) * 1993-01-14 2000-02-22 Magainin Pharma Amino acids and peptides having modified c-terminals and modified n-terminals
WO2006093867A1 (en) * 2005-02-28 2006-09-08 The Rockefeller University Structure of the hepatitits c virus ns5a protein
US20100158862A1 (en) * 2006-08-11 2010-06-24 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US7759495B2 (en) * 2006-08-11 2010-07-20 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) * 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG171891A1 (en) * 2008-12-03 2011-07-28 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
CN103819537A (zh) * 2009-06-11 2014-05-28 艾伯维巴哈马有限公司 抗病毒化合物

Also Published As

Publication number Publication date
BRPI1014084A2 (pt) 2016-04-19
CL2011002453A1 (es) 2012-03-02
WO2010117704A1 (en) 2010-10-14
JP2012522056A (ja) 2012-09-20
US20100249190A1 (en) 2010-09-30
EP2414352B1 (en) 2014-10-01
PE20120517A1 (es) 2012-05-09
AU2010234861A1 (en) 2011-09-22
MX2011009644A (es) 2011-09-28
NZ594981A (en) 2013-05-31
ZA201106669B (en) 2013-02-27
CA2758047C (en) 2016-05-17
CO6361922A2 (es) 2012-01-20
EP2414352A1 (en) 2012-02-08
CN102378762A (zh) 2012-03-14
CN102378762B (zh) 2014-10-29
EA201101240A1 (ru) 2012-05-30
TW201038555A (en) 2010-11-01
ES2524542T3 (es) 2014-12-10
US20120277266A1 (en) 2012-11-01
CA2758047A1 (en) 2010-10-14
KR20110134497A (ko) 2011-12-14
EA021260B1 (ru) 2015-05-29
JP5612661B2 (ja) 2014-10-22
US8822444B2 (en) 2014-09-02
IL214939A0 (en) 2011-11-30
TWI476190B (zh) 2015-03-11

Similar Documents

Publication Publication Date Title
AR076170A1 (es) Derivados heterociclicos imidazolicos y/o oxazolicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
AR076002A1 (es) Derivados imidazolicos heterociclicos utiles como agentes antivirales para hepatitis c y composiciones farmaceuticas que los comprenden.
AR088829A1 (es) DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3
CO5700763A2 (es) Derivados de 1-bencil-5-piperazin-1-il-3,4-dihidro-1h-quinazolin-2-ona y el respexctivo 1h-benzo (1,2,6)tiadiazin-2,2-dioxido y derivados de 1,4-dihidro-benzo (d) (1,3) oxazin-2-ona como moduladores del receptor 5-hidroxitriptamina (5-ht) para el tra
AR112774A1 (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona
AR076900A1 (es) Derivados heterociclicos nitrogenados utiles como agentes antivirales, composiciones farmaceuticas que los contienen y uso de los mismos como inhibidores del vhc
ES2600636T3 (es) Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2
AR075510A1 (es) Inhibidores del virus de la hepatitis c
ES2669189T3 (es) Compuestos de carbazol útiles como inhibidores del bromodominio
AR080314A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido (1,2-a) pirazina y su uso como inhibidor de la hiv integrasa
ES2354569T3 (es) Antagonistas del receptor de histamina-3.
AR083953A1 (es) Compuestos para tratar enfermedades neurodegenerativas
NI201000120A (es) Derivados de ftalazinona
ES2607952T3 (es) Derivados tricíclicos de Pirazol Amina
UY31014A1 (es) Derivados de ftalazinona
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
AR088226A1 (es) Derivados piperidinicos heterociclicos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades neurodegenerativas
PE20181304A1 (es) Derivados de indol n-sustituidos como moduladores de los receptores de pge2
AR056861A1 (es) Compuestos triciclicos fusionados como inhibidores de la necrosis tumoral. composiciones farmaceuticas y procesos de obtencion
AR059961A1 (es) Compuesto derivado de fenil tetrahidro-indazol, composiciones farmaceuticas que lo comprenden, usos para preparar un medicamento para el tratamiento de una enfermedad mediada por una reduccion o desequilibrio en la funcion del receptor de glutamato y procesos para su preparacion
CO6251352A2 (es) Derivados de ciclopentanodiona activos como herbicidas
ES2603931T3 (es) Compuestos de triazolo
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
AR056025A1 (es) Compuestos de imidazol sustituidos como inhibidores de ksp

Legal Events

Date Code Title Description
FB Suspension of granting procedure